X4 Pharmaceuticals (XFOR) Misses Q4 EPS by 56c

Go back to X4 Pharmaceuticals (XFOR) Misses Q4 EPS by 56c

X4 Pharmaceuticals (XFOR) PT Lowered to $10 at Stifel

March 17, 2022 12:43 PM EDT

Stifel analyst Stephen Willey lowered the price target on X4 Pharmaceuticals (NASDAQ: XFOR) to $10.00 (from $18.00) while maintaining a Buy rating.

... More